You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Advanced or Recurrent Endometrial Carcinoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Endometrial Cancer, Endometrioid Tumor, Cancer Trial in Oklahoma City (nab-sirolimus)

Not yet recruiting
  • Endometrial Cancer
  • +5 more
  • Oklahoma City, Oklahoma
    University Oklahoma Stephenson Cancer Center
Aug 16, 2023

Endometrial Carcinoma Trial (Lerociclib, Letrozole 2.5mg, Placebo)

Not yet recruiting
  • Endometrial Carcinoma
  • (no location specified)
Jan 26, 2023

Recurrent Endometrial Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Carcinoma Trial in

Recruiting
  • Recurrent Endometrial Carcinoma
  • +12 more
  • Houston, Texas
  • +1 more
Sep 22, 2022

Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer Trial in Shanghai (SHR-1210, Famitinib)

Recruiting
  • Renal Cell Carcinoma
  • +4 more
  • Shanghai, Shanghai, China
    Huadong Hospital Affiliated to Fudan University
Jun 30, 2022

Endometrial Cancer Trial in Israel, United States (Selinexor, Matching Placebo for selinexor)

Recruiting
  • Endometrial Cancer
  • Miami Beach, Florida
  • +6 more
Jan 31, 2023

Breast Cancer, Lung Cancer, Colorectal Cancer Trial in Kobe (e-PRO monitoring)

Enrolling by invitation
  • Breast Cancer
  • +7 more
  • e-PRO monitoring
  • Kobe, Hyogo, Japan
    Kobe University Graduate School
Jun 27, 2023

Pattern & Outcomes of Advanced, Recurrent or Metastatic

Completed
  • Oncology
  • +4 more
  • Argenteuil, France
  • +29 more
Jan 23, 2023

Ovarian Cancer, Endometrial Cancer, Recurrent Ovarian Cancer Trial (BKM120, Nabpaclitaxel)

Withdrawn
  • Ovarian Cancer
  • +3 more
  • (no location specified)
Jul 27, 2022

Endometrial Carcinoma Trial in Changsha, Jinan (TQB2858 injection, Anlotinib Hydrochloride capsules)

Not yet recruiting
  • Endometrial Carcinoma
  • TQB2858 injection
  • Anlotinib Hydrochloride capsules
  • Changsha, Hunan, China
  • +1 more
Nov 18, 2021

Triple Negative Breast Cancer, Endometrial Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer Trial run by the

Completed
Has Results
  • Triple Negative Breast Cancer
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Dec 17, 2021

Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma Trial in United States

Completed
Has Results
  • Endometrial Adenocarcinoma
  • +4 more
  • Akt Inhibitor MK2206
  • Laboratory Biomarker Analysis
  • Boston, Massachusetts
  • +6 more
Jan 13, 2022

Solid Tumor, Adult, Carcinoma, Ovarian Epithelial, Fallopian Tube Tumors Trial in Houston (BP1001-A (Liposomal Grb2 Antisense

Not yet recruiting
  • Solid Tumor, Adult
  • +5 more
  • BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)
  • BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel
  • (no location specified)
Jun 7, 2022

Endometrial Cancer Trial in Pensacola, Voorhees, Houston (Metformin, Letrozole, Everolimus)

Active, not recruiting
  • Endometrial Cancer
  • Pensacola, Florida
  • +5 more
Feb 9, 2022

Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma Trial in Canada, United States

Active, not recruiting
  • Advanced Endometrial Carcinoma
  • +4 more
  • Cabozantinib S-malate
  • Nivolumab
  • Phoenix, Arizona
  • +33 more
Nov 1, 2022

Ovarian Cancer, Ovarian Tumors, Ovarian Carcinoma Trial in United States (ELU001)

Recruiting
  • Ovarian Cancer
  • +68 more
  • Phoenix, Arizona
  • +8 more
Aug 18, 2022

Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent Trial in United States (RGX-104, Nivolumab, Ipilimumab)

Recruiting
  • Endometrial Cancer
  • +5 more
  • Los Angeles, California
  • +13 more
Jul 21, 2022

Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma Trial (Biopsy, Biospecimen

Not yet recruiting
  • Metastatic Endometrial Carcinoma
  • +7 more
  • Biopsy
  • +5 more
  • (no location specified)
Jan 18, 2023

Endometrial Cancer, Endometrial Adenocarcinoma Trial (Cadonilimab, Carboplatin, Cisplatin)

Not yet recruiting
  • Endometrial Cancer
  • Endometrial Adenocarcinoma
  • (no location specified)
Oct 7, 2023

Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma Trial in

Recruiting
  • Recurrent Endometrial Adenocarcinoma
  • +8 more
  • Ipilimumab
  • Nivolumab
  • Iowa City, Iowa
  • +9 more
Jan 27, 2023

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Beijing (HS-20089)

Not yet recruiting
  • Ovarian Cancer
  • +3 more
  • Beijing, Beijing, China
    Lingying Wu
Aug 22, 2023

Endometrial Cancer Trial (Navtemadlin, Navtemadlin Placebo)

Not yet recruiting
  • Endometrial Cancer
  • (no location specified)
Mar 21, 2023

Endometrial Cancer Trial in Houston (DKN-01, Pembrolizumab)

Not yet recruiting
  • Endometrial Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Feb 27, 2023

Endometrial Tumors Trial in China (Lenvatinib, Pembrolizumab, Paclitaxel)

Active, not recruiting
  • Endometrial Neoplasms
  • Hefei, Anhui, China
  • +21 more
May 6, 2022

Recurrent Endometrial Carcinoma, Unresectable Endometrial Carcinoma Trial in Miami (Lenvatinib, Pembrolizumab, Hypofractionated

Not yet recruiting
  • Recurrent Endometrial Carcinoma
  • Unresectable Endometrial Carcinoma
  • Miami, Florida
    University of Miami
Jan 10, 2023

Endometrial Cancer Trial in Morristown, Houston (Letrozole, RAD001 (Everolimus))

Active, not recruiting
Has Results
  • Endometrial Cancer
  • Morristown, New Jersey
  • +1 more
Nov 16, 2022